Spruce Biosciences, Inc. (SPRB)

Spruce Biosciences' stock experienced significant volatility in the past six months. In October 2025, the stock surged following the FDA's Breakthrough Therapy Designation for TA-ERT, increasing by over 250% in a single day. Prior to this, the company faced setbacks, including a stock plunge and Nasdaq delisting in April 2025 after its Phase 2b trial for tildacerfont failed. As of November 2025, the stock has been trading around $104.57 to $110.00.

There is no indication of demand seasonality for Spruce Biosciences' products or services. The demand for treatments for rare diseases is typically driven by medical need rather than seasonal factors.

Spruce Biosciences, Inc. is a late-stage biopharmaceutical company focused on developing therapies for rare endocrine and neurological disorders. Initially focused on Congenital Adrenal Hyperplasia (CAH) with tildacerfont, the company shifted its focus after a failed Phase 2b trial. Spruce Biosciences acquired tralesinidase alfa (TA-ERT) for Sanfilippo Syndrome Type B (MPS IIIB) and plans to submit a BLA to the FDA in Q1 2026.

Spruce Biosciences, Inc. is headquartered in South San Francisco, California. The company plans to establish commercial operations in the U.S., EU, and the U.K., and will seek collaborations and distributors in other international markets.

Spruce Biosciences' brand reputation experienced a turnaround in the past year. The failure of tildacerfont in a Phase 2b trial negatively impacted its reputation, leading to a Nasdaq delisting in April 2025. However, the FDA's Breakthrough Therapy Designation for tralesinidase alfa (TA-ERT) in October 2025 significantly boosted the company's reputation and investor confidence.

Spruce Biosciences, Inc. has significant institutional ownership, with 91.71% of its stock held by institutions. Major institutional owners include Carlyle Group Inc., VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Cable Car Capital LLC, Ikarian Capital, LLC, Lion Point Capital, LP, Advisor Group Holdings, Inc., UBS Group AG, Morgan Stanley, Caldwell Securities, Inc, and Bank Of America Corp /de/. Insiders hold 6.90% of the stock.